Frequency of treatment-emergent cGVHD by site of disease after anti–PD-1 administration
| . | cGVHD score . | ||
|---|---|---|---|
| 1 (mild); n = 11 . | 2 (moderate); n = 10 . | 3 (severe); n = 5 . | |
| Skin | 4 | 3 | 0 |
| GI | 1 | 3 | 0 |
| Liver | 2 | 1 | 2 |
| Ocular | 2 | 1 | 1 |
| Oral | 2 | 1 | 2 |
| Joints/fascia | 0 | 1 | 0 |
| . | cGVHD score . | ||
|---|---|---|---|
| 1 (mild); n = 11 . | 2 (moderate); n = 10 . | 3 (severe); n = 5 . | |
| Skin | 4 | 3 | 0 |
| GI | 1 | 3 | 0 |
| Liver | 2 | 1 | 2 |
| Ocular | 2 | 1 | 1 |
| Oral | 2 | 1 | 2 |
| Joints/fascia | 0 | 1 | 0 |
cGVHD stage/grade and responses were scored according to NIH criteria. Each episode of GVHD was recorded as either acute or chronic, although some patients experienced aGVHD and cGVHD, which were counted as mutually exclusive events.